Apnimed company information, Employees & Contact Information

Apnimed to Participate in the 5th Annual Needham Private Biotech and MedTech Company Virtual 1x1 Forum PR Newswire

Apnimed To Present Additional Phase 3 Data for AD109, an Investigational Oral Pill for Obstructive Sleep Apnea, at CHEST 2025 Annual Meeting Eastern Progress

Platform linked to ring pulse oximeter monitors, analyzes night-to-night sleep metrics Healio

Investigational AD109 Meets End Points in Phase 3 LunAIRo Trial, Eyeing FDA Submission for Obstructive Sleep Apnea NeurologyLive

Positive Topline Results From Phase 3 Trial of AD109, First Oral Pill for Obstructive Sleep Apnea Psychiatric Times

Apnimed Announces Acceptance of Two Late-breaking Presentations and a Core Interactive Session at the CHEST Annual Meeting Highlighting New Positive AD109 Phase 3 Data and the Current Unmet Need in Obstructive Sleep Apnea WV News

Wearable sensor could be used to monitor OSA treatment response EurekAlert!

Once-Daily Oral Pill for Obstructive Sleep Apnea Shows Promising Phase 3 Results, Paving Way for FDA Submission NeurologyLive

Topline results: Oral drug lowers OSA severity over 6 months Healio

Apnimed Announces Multiple Presentations at the American Thoracic Society (ATS) International Conference 2025 Highlighting Novel Techniques and Unmet Medical Needs in Sleep Medicine PR Newswire

Apnimed announces positive results from second clinical trial of sleep apnea medication American Academy of Sleep Medicine | AASM

Apnimed's sleep apnea asset goes 2 for 2 in phase 3, solidifying star potential Fierce Biotech

Apnimed Announces Multiple Presentations at the Associated Professional Sleep Societies (SLEEP 2025) Annual Meeting Highlighting the Disease Burden and Current Unmet Medical Needs in Obstructive Sleep Apnea (OSA) PR Newswire

Apnimed to Host Virtual Investor Event Highlighting the Potential for AD109 as a Novel Pharmacotherapy for Obstructive Sleep Apnea on April 11, 2025 PR Newswire

Topline results: Oral drug combination lowers OSA severity over 51 weeks Healio

Apnimed Provides Clinical Updates for Multiple Product Candidates PR Newswire

Patients with OSA commonly report fatigue, lost work productivity, limited daily activity Healio

Apnimed Appoints Kevin R. Lind as Non-Executive Chairman of the Board of Directors PR Newswire

Apnimed Strengthens Executive Team and Board of Directors with the Appointment of Two Biopharmaceutical Industry Veterans PR Newswire

Efficacy of Apnimed's Novel Oral Formulation Targeting OSA Confirmed in Second Phase 3 Trial Patient Care Online

Apnimed announces positive results in clinical trial of sleep apnea medication American Academy of Sleep Medicine | AASM

Performance evaluation of a ring-worn pulse oximeter for the identification and monitoring of obstructive sleep apnea Frontiers

Studying an Oral Nighttime Therapy in Mild to Severe Obstructive Sleep Apnea: The LunAIRo Trial NeurologyLive

AASM announces finalists for first Sleep Medicine Disruptors Innovation Award American Academy of Sleep Medicine | AASM

Mechanism and Rationale Behind AD109 for Obstructive Sleep Apnea: Patrick Strollo, MD, FACP, FCCP, FAASM NeurologyLive

Celebrating World Sleep Day across specialties: OSA ‘touches every organ’ Healio

A Pill for Sleep Apnea Could Be on the Horizon The New York Times

Apnimed Appoints John Yee, MD, MPH, as SVP, Medical Affairs Yahoo Finance

AD109 Improves OSA in Phase 3 SynAIRgy Trial, With Patrick Strollo, MD HCPLive

Apnimed Announces New Leadership Appointments as the Company Builds Its Commercial and Human Resource Capabilities in Support of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea GlobeNewswire

Apnimed eyes sleep apnea drug submission after positive phase 3 results Fierce Biotech

Investigational Oral Medication for OSA Meets Primary Endpoints in Phase 3 Clinical Trial Patient Care Online

Viloxazine with or without trazodone decreases OSA severity Healio

Development of a combination of noradrenergic and antimuscarinic drugs for the treatment of obstructive sleep apnea: Challenges and progress Frontiers

The future of sleep apnea management: we can either ride the bus or drive it Frontiers

Apnimed’s oral sleep apnea candidate hits phase III endpoints BioWorld MedTech

Oral combination obstructive sleep apnea drug lowers disorder severity over 1 month Healio

Eyeing Neurology Drug Development: 2H Trial Readouts to Watch for in 2025 NeurologyLive

Apnimed Appoints John Cronin, M.D., as Senior Vice President citybiz

Japan's Shionogi announces further agreement with Apnimed for sleep disorder treatments BioSpectrum Asia

Apnimed Announces $62.5 Million Series C Financing to Advance Development of Novel Pharmaceutical Treatments for Obstructive Sleep Apnea (OSA) and Related Sleep Disorders Business Wire

Aroxybutynin plus atomoxetine novel oral therapy for obstructive sleep apnea: MARIPOSA phase 2b trial Medical Dialogues